Intrinsic subtypes in Ethiopian breast cancer patient

Zelalem Desalegn1,2 · Meron Yohannes3 · Martin Porsch4 · Kathrin Stückrath5 · Endale Anberber6 · Pablo Santos7 · Marcus Bauer2,8 · Adamu Addissie9 · Yonas Bekuretsion10 · Mathewos Assefa11 · Yasin Worku12 · Lesley Taylor13 · Tamrat Abebe1 · Eva Johanna Kantelhardt5,7 · Martina Vetter5

Received: 9 August 2022 / Accepted: 6 October 2022 / Published online: 25 October 2022 © The Author(s) 2022

Abstract

Purpose The recent development of multi-gene assays for gene expression profiling has contributed significantly to the understanding of the clinically and biologically heterogeneous breast cancer (BC) disease. PAM50 is one of these assays used to stratify BC patients and individualize treatment. The present study was conducted to characterize PAM50-based intrinsic subtypes among Ethiopian BC patients.

Patients and methods Formalin-fixed paraffin-embedded tissues were collected from 334 BC patients who attended five different Ethiopian health facilities. All samples were assessed using the PAM50 algorithm for intrinsic subtyping.

Results The tumor samples were classified into PAM50 intrinsic subtypes as follows: 104 samples (31.1%) were luminal A, 91 samples (27.2%) were luminal B, 62 samples (18.6%) were HER2-enriched and 77 samples (23.1%) were basal-like. The intrinsic subtypes were found to be associated with clinical and histopathological parameters such as steroid hormone receptor status, HER2 status, Ki-67 proliferation index and tumor differentiation, but not with age, tumor size or histological type. An immunohistochemistry-based classification of tumors (IHC groups) was found to correlate with intrinsic subtypes.

Conclusion The distribution of the intrinsic subtypes confirms previous immunohistochemistry-based studies from Ethiopia showing potentially endocrine-sensitive tumors in more than half of the patients. Health workers in primary or secondary level health care facilities can be trained to offer endocrine therapy to improve breast cancer care. Additionally, the findings indicate that PAM50-based classification offers a robust method for the molecular classification of tumors in the Ethiopian context.

Keywords Ethiopia · Breast cancer · PAM50 · Intrinsic subtyping
Introduction

Breast cancer (BC) is one of the most commonly diagnosed cancer worldwide with an estimated 2.3 million new cases in 2020. Improved screening, systemic drug treatment such as endocrine therapy, chemotherapy, targeted therapy, immunotherapy, and surgery, radiotherapy have contributed significantly in reducing mortality [1]. In the resource-limited settings, BC incidence and mortality tend to increase [2]. In the context of Sub-Saharan Africa, access to diagnosis and cancer care have been identified as important determinants for survival [3]. In Ethiopia, BC is one of the most common cancers [4]. Previous survival studies demonstrated that women in Ethiopia had a favorable 5-year outcome with 45% metastasis free survival [5]. In another study in rural Ethiopia, the 2-year overall survival was only 53% [6].

Prognostic and predictive factors such as age, tumor size, nodal status, grading, Ki-67 proliferation index, angiogenesis, hormone receptor (HR) status, human epidermal growth factor receptor 2 (HER2) status are used in the clinical routine for prognosis of the patient and predicting benefit from therapy [7]. In addition, molecular biomarkers have an increasingly important role tailoring the individualized treatment recommendation for BC patients in the selection of chemotherapy, endocrine or immunotherapy regimen [8].

Gene expression analysis has helped identify distinct molecular signatures in breast cancer that have different prognostic outcomes in addition to clinical and histopathological features. Multi-gene assays in early breast cancer are now routinely used in clinical practice and are integrated into national and international guidelines [9]. Parker and colleagues simplified the profiling algorithms using 50 genes for classification in one of the intrinsic subtypes: luminal A, luminal B, HER2-enriched, and basal-like [10, 11]. The PAM50 classifier provides in addition to traditional clinical and histopathological biomarkers prognostic and predictive value for BC patients [11].

Studies from different regions in Africa have reported proportions of estrogen receptor-positive disease varying between 20 and 70% supposedly due to differences in genetic background, tumor size, but also quality issues have been discussed [12]. Our own data from Ethiopia showed 65% estrogen receptor-positive tumors assessed by immunohistochemistry [13]. The present study was conducted to assess the performance of the PAM50 classifier in Ethiopian breast cancer specimens and to assess associations of the intrinsic subtypes with protein expression of estrogen receptor, progesterone receptor and HER2.

Patients and methods

Patients and samples

All female patients with invasive carcinoma of the breast were included in this study in accordance with the REMARK criteria [14]. Formalin-fixed paraffin-embedded (FFPE) tissues from pathologically confirmed BC samples (n = 334) were collected by ZD and MY from different hospitals and pathology laboratories in Ethiopia (Tikur Anbessa Specialized Hospital, Zewditu Memorial Hospital, Yekatit 12 Hospital, Bethzatha General Hospital, St. Paul’s Hospital Millennium Medical College, Aira General Hospital). Clinical and histopathological data including age at diagnosis, tumor size, histologic type and tumor differentiation were retrieved from patient’s medical records. An overview of all parameters considered here is given in the Supplementary Table S1.

IHC and gene expression analysis

FFPE tissue was employed for the analysis of the expression of ER, PgR, HER2, and Ki-67 using immunohistochemistry (IHC). IHC analyses were carried out using specific antibodies according to the manufacturers’ instructions as follows:

- ER: Clone Ab-11; Thermo Scientific, MA; USA, Catalog Number MS-354-P1, mouse host, dilution 1:150
- PgR: Clone PgR 636; DAKO, CA, USA, Catalog Number M3569, mouse host, dilution 1:100
- HER2: Clone DG44; DAKO, CA, USA, Catalog Number SK001, rabbit host, ready to use
- Ki-67: Clone SP6; Thermo Scientific, MA, USA, Catalog Number RM-9106-S; mouse host; dilution 1:250

Expression of HR and HER2 status was performed according to the current guidelines [15], positivity of ER and PgR status was declared when the IRS was > 0. If at least one of the markers were positive, the HR status was defined as positive. HER2 status was assessed according to ASC-CAP guidelines [16]. HER2 DAKO 3 was considered positive, HER2 DAKO 0 and DAKO 1 was considered HER2-negative. Tissue with HER2 DAKO 2 was interpreted as equivocal and cromogen in situ hybridization (CISH) was performed for confirmation. Based on previous reports, Ki-67 proliferation index was graded as ‘low’
if Ki-67 staining was positive in <20% of tumor cells or ‘high’ when at least 20% of tumor cells stained positive [17, 18]. The histological grading was performed using Elston–Ellis grading system [19].

After identification of the tumor areas on HE-stained slides by the pathologist, 3–5 adjacent unstained tumor slides (10 µm) were processed using miRNeasy FFPE Mini Kit® (Qiagen) according to the manufacturer’s protocol. The extracted RNA concentration and quality was measured using Nanophotometer.

Relative gene expression was measured using the NanoString nCounter® Analysis System (NanoString Technologies, Seattle, WA, USA) using a multiplexed hybridization assay, digital readouts of fluorescent barcoded probes which hybridize with each mRNA sequence of interest. The data collection was carried out in the nCounter® Digital Analyzer. Data import, quality control, and normalization of expression levels were conducted with the nSolver software version 4 (NanoString Technologies, Inc.). Background subtraction from raw transcript counts was performed through negative input controls. Following reference-normalization by dividing the geometric mean of six references-control genes (ACTB, G6PD, RPLP0, TBP, TFRC and UBB), normalized counts were log2-transformed prior to all downstream analyses. Intrinsic subtype classification was calculated using the nearest PAM50 centroid algorithm Bioclassifier and NanoStringNorm implemented in R [11, 20].

Endpoints and statistical analysis

As a first objective, the distribution of the intrinsic subtypes within an Ethiopian cohort was defined. The secondary objectives were the associations of the intrinsic subtypes to clinical and histopathological parameters including the IHC groups, applying logistic regression. In order to tackle multiple testing, we reduced the subgroup analyses to pre-defined, well-accepted and clinical relevant groups (e.g., age, tumor size, tumor grade/differentiation, ER status, PgR status, HER2 status, Ki-67 proliferation index and IHC groups). Statistical significance was declared for p-values < 1% (two-sided Pearson’s chi-square tests for independence, with Yates’ correction for continuity when relevant). Statistical analyses were carried out using SPSS 25 (IBM, Armonk NY, USA).

Results

Distribution of intrinsic subtypes

The classification of intrinsic subtypes based on the PAM50 assay yielded 104 luminal A (31.1%), 91 luminal B (27.2%), 62 HER2-enriched (18.6%) and 77 basal-like samples (23.1%). The expression levels of the 50 loci included in the assay (Fig. 1) revealed a gene expression signature which was unique for each subtype. An overview of the distribution of selected clinical and histopathological parameters among the PAM50-based intrinsic subtypes is given in Table 1.
A strong correlation was observed between intrinsic subtypes and IHC groups (p-value from χ² test for independence < 0.001, Fig. 2). This association was driven mainly by the luminal subtypes, from which 81.6% (n = 158) were grouped as HR-positive and HER2-negative (Fig. 2, upper left). A multivariate regression allowed us to confirm the strong correlation (ORs > 20) between the luminal intrinsic subtypes and the HR+/HER2–IHC group, after adjusting for age, tumor size, histological type, tumor grade and Ki-67 proliferation index (Table 2).

Out of the 62 samples classified as HER2-enriched, 66.1% (n = 41) were defined as HER2–positive irrespective of HR status (Fig. 2). The results of a multivariate regression confirmed this, as HER2-enriched samples were significantly associated with a very high probability of being HER2-positive (independent of HR status, ORs > 20, Table 2). HER2-enriched samples were also associated with TNBC, although with a lower odds ratio (OR 6.7, 99% CI 1.77–25.39, Table 2).

The samples classified as basal-like had an increased probability of being TNBC (46 of 77 samples, 60%), as compared with triple-positive (HR+/HER2+) samples (Table 2).

### Intrinsic subtypes and histopathological parameters

Luminal A samples had a more than three-fold increased probability for favorable characteristics such as higher tumor differentiation (G1 or G2) and low Ki-67 proliferation index (OR 3.19, 99% CI 1.47–6.92 and OR 3.65, 99% CI 1.72–7.72, respectively, Table 2). Basal-like samples were
associated with lower differentiation (G3; OR 3.43, 95% CI 1.26–9.34, Table 2). No further significant associations between intrinsic subtypes and histopathological parameters were found. A detailed analysis focused on the whole measured range of the prognostic parameters ER, PgR, HER2 and Ki-67 proliferation index is visualized in Fig. 3. While the IRS scores of ER and PgR spanned evenly between 0 and 12 for both luminal subtypes, these accumulated below IRS 2 for HER2-enriched and basal-like samples (Fig. 3A, B). This underlines the associations described between intrinsic subtypes and the expression of the steroid hormone receptors detected by IHC (see Table S2 for binary assessments). The violin plot of DAKO scores made the aforementioned association between HER2-enriched samples and positive HER2 status evident. The accumulation of scores > 2 was almost exclusively seen in HER2-enriched samples (Fig. 3C; Table S2). Similarly, specimens of low proliferation rates (< 20%) were more likely to be of the luminal A subtype (Fig. 3D; Table S2). However, low proliferation rates were also present in the other intrinsic subtypes. The highest proliferation rates were observed among basal-like samples.

Discussion

In this prospective cohort of Ethiopian patients with BC, intrinsic PAM50-based subtypes of tumors were determined in addition to receptor status by immunohistochemistry (n = 334). Both methods had considerable similarities, especially for basal-like or triple-negative and HER2-enriched or HER2-positive types. The high proportion of patients below the age of 50 (approx. 60%) and large tumor sizes (T3 and T4, approx. 40%) differed from high-income settings. This probably resulted in the lower proportions of luminal A subtypes compared to Western cohorts.

Pattern of subtypes

We reported in 2014 that two thirds of tumors from a patient cohorts from Addis Ababa had endocrine responsive disease [13]. Another cohort from rural Ethiopia showed more than half of the patients with positive hormone receptor status [6]. The third study published in 2018 again from Addis Ababa also reported 65% of receptor-positive disease [21]. Within the current study, immunohistochemistry as well as RNA-expression analysis were used to assess endocrine responsiveness. The results also revealed that even using RNA-expression based subtyping, more than half of the tumors were endocrine responsive. In detail, we found 31.1% luminal A, 27.2% luminal B, 18.6% HER2-enriched and 23.1% basal-like tumors. This is considerably shifted to the more aggressive subtypes compared, for example, to data from the United States (Nurses Health Study) that reported 46% luminal A, 18% luminal B, 14% HER2-enriched, 15% basal-like, and 8% normal-like subtypes [22]. Such direct comparison needs to be interpreted with care.

Comparing with other ethnic groups

High quality data on tumor subtypes from the cancer genome atlas about tumors from African patients is lacking. Patients with African compared to European ancestry had a higher likelihood of basal-like (odds ratio OR 1.67) and HER2-enriched (OR 2.22) tumors [23]. African–American patients genetic background has been reported as predominantly from West Africa [24].

Geographic variations have been observed across Africa concerning the composition of different hormone receptor-based types no longer characterizing all tumors in Africa as having aggressive phenotypes. A large meta-analysis found that patterns of tumor subtypes in East Africa appear to be more favorable compared to other geographic regions such as West Africa [12].
Other factors influencing subtype composition

Our convenient hospital cohort has specific features. The age composition as well as proportions of early and later stage disease may influence the overall proportions of subtypes. In general, cohorts from sub Saharan Africa seem to similarly represent a young population and commonly comprise of late stage tumors compared to Western settings. It was shown in a cohort from the United States that patients with luminal A tumors are on average 5–6 years older than patients with the other subtypes [25]. A comparison of receptor status between Sudanese and German patients also showed considerably more low-grade, receptor-positive tumors in older German women [26]. Therefore cohorts with fewer older patients lack these luminal tumors. Additionally, body composition has been reported to influence subtype. Obesity has been associated with higher risk of luminal A type breast cancer [27]. Since obesity is still rare in Ethiopia, less luminal A breast cancers are expected [28].

Comparing subtypes and IHC

Assessing tumor biology with RNA-expression analysis is considered gold standard, at the same time immunohistochemistry has been used as basis to prove effectiveness of endocrine treatment. When comparing both methods,
certain discrepancies can be seen. Consistent with previous reports [29], we have observed a substantial mismatch between the classification based on gene expression (PAM50 intrinsic subtypes) and on immunohistochemistry (IHC groups using ER, PgR and HER2). Still, hormone receptor-positive tumors were mainly classified as luminal subtypes. Therefore, immunohistochemistry results appear reliable as a basis for decision to advise endocrine treatment to the patient despite lack of standardized external quality assurance measures for tissue processing and immunohistochemistry performance [30].

In Ethiopia, as well as many other countries in Sub-Saharan Africa, basic immunohistochemistry is not always accessible to all patients. Even in capital cities, 15 out of 20 centers experienced frequent power cuts and four out of twenty had no immunohistochemistry in the country [31]. Due to the fact that also for Ethiopian patients’ routine immunohistochemistry is not always available, several confirmatory studies reported that half of patients have endocrine responsive disease (confirmed by RNA-expression as well as immunohistochemistry studies). This may provide clinicians more confidence in their decision process to offer endocrine treatment for patients with unknown receptor status.

**Individualized therapy**

As a future perspective, multiplexed hybridization assay-based subtype determination via nCounter® can also support individualized therapy in Ethiopia. Since a large proportion of tumors are larger than 2 cm or lymph node-positive, without additional prognostic markers, according to the National Cancer Control Network (NCCN) harmonized guidelines, nearly all patients would need chemotherapy. As an example, utilizing PAM50-based subtypes, we were able to split the large group of patients with HR-positive and HER2-negative tumors into clinically relevant, more homogenous intrinsic subtypes. Patients with HR+/HER2 tumors have been regarded as an especially challenging BC group due to high variance concerning clinical outcome [32]. These patients include cases of low, intermediate and high risk of recurrence. Differentiating the HR+/HER2 group into luminal A and non-luminal A intrinsic subtypes increases the ability to assess recurrence risk in a more individualized manner, since chemotherapy is not recommended for patients with luminal A tumors [33, 34]. This information also enables clinicians to counsel patients on the importance of adherence to adjuvant endocrine therapy long-term and surveillance for local or distant recurrence.

**Individualized therapy: HER2-enriched and basal-like types**

The subtype determination can also personalize treatment for patients with aggressive tumors. The PAM50 assay allowed the identification of 62 tumors as HER2-enriched, regardless of HER2 status. Using the IHC method, only 41 patients would get an anti-HER2 therapy. This means that the PAM50 assay leads to an approximately 50% incremented number of patients who would benefit from drugs suppressing the HER2 signaling pathway (anti-HER2 therapy). Our results are concordant with the seminal work of Perou and colleagues in the sense that two thirds of our samples classified as HER2-positive were found to be HER2-enriched (Table 1) [10].

Finally, 77 samples were classified as basal-like through the PAM50 assay. Out of these, only 46 (60%) were concordant with the triple-negative class via the IHC method. These samples are arguably the ones that would benefit most from chemotherapy, 40% of the basal-like samples are non-TNBC [10]. Conversely, approximately 38% of the TNBC tumors were non-basal-like. Thus, both PAM50 and IHC classification methods yield heterogeneous groups where personalized recommendations would improve by additional molecular subtyping as proposed before [35, 36].

**Fig. 3** Scores of Estrogen Receptor, Progesterone Receptor, HER2 and Ki-67 Proliferation Index among intrinsic subtypes. The horizontal widths of the violin plots correspond to the frequency distribution of data points. Horizontal bars shown in the plots denote data available for those values. ER estrogen receptor, PgR progesterone receptor, IRS immune-reactive score, ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2.
Strengths and limitations

The strength of the study includes multi-center involvement in Ethiopia and the application of multigene assays for gene expression profiling which is the gold standard for molecular classification as well as hormone receptor status by immunohistochemistry involving relatively large sample size. Both methods similarly showed a large share of endocrine responsive tumors. Certain limitations have to be taken into account. Firstly, the cohort is a convenient hospital-based sample and does not reflect the true pattern within the population. Given the resource-limited setting, population-based sample collection is not feasible. Secondly, Ethiopian patients vary considerably linguistically, ethnically and culturally within the country. Therefore results cannot be generalized within the country and a nation-wide study investigating distribution intrinsic subtypes and further exploration of tumor biology is essential to capture the large number of different ethnic groups in Ethiopia which could possibly help to have a broaden understanding of BC biology.

Conclusion

To our knowledge, this is the first time that a large African BC patient group is characterized by molecular expression profiling. In summary, we confirmed previous immunohistochemistry results showing a considerable proportion of more than half the patients eligible for endocrine treatment. This allows utilization of a cost-effective treatment with very little side-effects that can be administered even at primary or secondary level health facilities. A study from Ethiopia proved that a strategy involving the specialized training of “cancer nurses” to support patients during their 5 year treatment can improve adherence [37].

Efforts are needed to provide sufficient access to immunohistochemistry service but in the meantime can encourage to utilization of endocrine treatment for patients with unknown receptor status. Within this project, colleagues from Ethiopia (ZD, MY, TA) received thorough training in tumor-banking, RNA-extraction and PAM50 subtyping. Additionally, during the time of the study and still ongoing is a larger training program to implement routine immunohistochemistry at Addis Ababa University involving weekly virtual meetings for case-discussions, several training courses in Ethiopia as well as in person mentorship in Germany. In 2022, consumables were provided and routine IHC for ER, PgR and HER2 determinations are performed in Ethiopia. Endpoint-PCR for research only was also implemented at Addis Ababa University as a step to further develop capacity in laboratory techniques. Since molecular methods are becoming available at lower prices, utilization of RNA-expression-based subtype assessment could become an option to optimize personalized treatment. One-step PCR technologies to assess basic receptor status are a possible compromise given the robustness of the methodology and at the same time relatively low cost availability.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s10549-022-06769-z.

Acknowledgements We would like to express our gratitude to the study participants and data collectors without whom it would have not been possible to realize the study. The authors are grateful for Susan. G. Komem for granting the research project. Last but not least, our heartfelt thanks go to Addis Ababa University for covering the tuition fee expense during my study.

Author contributions ZD contributed to study design, sample and data analysis, acquisition, interpretation and writing of the original and final draft. MY contributed to sample acquisition. MY, KS, EJK, MV, LT and TA contributed to study design, data acquisition, data analysis, data interpretation and editing of the manuscript. ZD, KS and MV carried out the experimental work. EA, YB, MA and YA contributed to data acquisition and editing of the manuscript. MP and PS contributed to data analysis, plotting and statistics. All authors reviewed and approved the final version of the manuscript.

Funding Open Access funding enabled and organized by Projekt DEAL. This study took advantage of grant by the Susan G. Komen organization assigned to the Medical Faculty of the Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (Grant No. GTDR16378013). This work was supported by Else-Kroener-Foundation through Martin-Luther-University, Halle-Wittenberg, Germany, Grant No. 2018_HA31SP. This study was also support by a grant from the German Academic Exchange Service to Martin-Luther-University, Halle-Wittenberg, Germany (ID 57216764). The study was also supported by a grant from Hospital partnership through Deutsche Gesellschaft für Internationale Zusammenarbeit funded by the Ministry for Economic Cooperation and Development and the Else-Kroener-Fresenius Foundation (ID 81256434). EJK also received an unrestricted grant from F. Hoffmann-La Roche Ltd (27.5.2014)—the funder was not involved in the design, analysis or publication of the study.

Data availability The data generated in this study are available within the article and its supplementary data files. Raw data were generated and processed from the authors and are available on request to the corresponding authors.

Declarations

Competing interest The authors have no relevant financial or non-financial interests to disclose.

Ethical approval This study was performed in line with the principles of the Declaration of Helsinki. Ethical approval was waived by the local ethics committee of all institutions. This work was carried out under IRB approved protocols at Addis Ababa University (Protocol Number 092/17/17) and Ethiopian National Research Ethical Review Committee (Protocol MOSHE/RD).

Informed consent Informed written consent was obtained from all participants.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Feng Y, Spezia M, Huang S et al (2018) Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis 5(2):77–106. https://doi.org/10.1016/j.gendis.2018.05.001

2. Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 71(3):209–249. https://doi.org/10.3332/caac.21660

3. Joko-Fru WY, Griesel M, Mezger NCS et al (2021) Breast cancer diagnostics, therapy, and outcomes in Sub-Saharan Africa: a population-based registry study. J Natl Compr Cancer Netw. https://doi.org/10.6004/jnccn.2021.7011

4. Timotewos G, Solomon A, Mathewos A et al (2018) First data from a population based cancer registry in Ethiopia. Cancer Epidemiol 53:93–98. https://doi.org/10.1016/j.canepe.2018.01.008

5. Kantelhardt EJ, Zerche P, Mathewos A et al (2014) Breast cancer survival in Ethiopia: a cohort study of 1070 women. Int J Cancer 135(3):702–709. https://doi.org/10.1002/ijc.28691

6. Eber-Schulz P, Tariku W, Reibold C et al (2018) Survival of breast cancer patients in rural Ethiopia. Breast Cancer Res Treat 170(1):111–118. https://doi.org/10.1007/s10549-018-4724-z

7. Gradishar WJ, Moran MS, Abraham J et al (2022) Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. doi:10.6004/jnccn.2022.0030

8. Andre F, Ismaila N, Allison KH et al (2020) Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol 40(16):1816–1837. https://doi.org/10.1200/JCO.20.00069

9. Giorgi Rossi P, Lebeau A, Canelo-Aybar C et al (2021) Recommendations from the European Commission initiative on breast cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative. Br J Cancer 124(9):1503–1512. https://doi.org/10.1038/s41416-020-01247-z

10. Perou CM, Sorlie T, Eisen M (2000) Molecular portraits of human breast tumours. Nature 406:747–752

11. Parker JS, Mullins M, Cheang MCU et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160–1167. https://doi.org/10.1200/JCO.2008.18.1370

12. Eng A, McCormack V, dos-Santos-Silva I (2014) Receptor-defined subtypes of breast cancer in indigenous populations in Africa: a systematic review and meta-analysis. PLoS Med. https://doi.org/10.1371/journal.pmed.1001720

13. Kantelhardt EJ, Mathewos A, Aynalem A et al (2014) The prevalence of estrogen receptor-negative breast cancer in Ethiopia. BMC Cancer 14:895. https://doi.org/10.1186/1471-2407-14-895

14. McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93(4):387–391. https://doi.org/10.1038/sj.bjc.6602678

15. Allison KH, Hammond MEH, Dowsett M et al (2020) Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol 38(12):1346–1366. https://doi.org/10.1200/JCO.19.02309

16. Wolff AC, Hammond MEH, Allison KH et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/College of American pathologists clinical practice guideline focused update. J Clin Oncol 36(20):2105–2122. https://doi.org/10.1200/JCO.2018.77.8738

17. Cheung MCU, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736–750. https://doi.org/10.1093/jnci/djp082

18. Dowsett M, Nielsen TO, A’Hern R et al (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in breast cancer working group. J Natl Cancer Inst 103(22):1656–1664. https://doi.org/10.1093/jnci/djr393

19. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403–410. https://doi.org/10.1111/j.1365-2559.1991.tb00229.x

20. Bercholdt E, Vetter M, Gündert M et al (2019) Comparison of six breast cancer classifiers using qPCR. Bioinformatics 35(18):3412–3420. https://doi.org/10.1093/bioinformatics/btz103

21. Hadgu E, Seifu D, Tigneh W et al (2018) Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa. BMC Womens Health 18(1):40. https://doi.org/10.1186/s12905-018-0531-2

22. Kessler KH, Sankar VN, Wang J et al (2018) PAM50 molecular intrinsic subtypes in the nurses’ health study cohorts. Cancer Epidemiol Biomark Prev 27(12):3021–3030. https://doi.org/10.1158/1055-9965.EPI-18-0663

23. Sweeney C, Bernard PS, Factor RE et al (2014) Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics. Cancer Epidemiol Biomark Prev 23(5):714–724. https://doi.org/10.1158/1055-9965.EPI-13-1021

24. Newman LA (2014) Breast cancer disparities: high-risk breast cancer and African ancestry. Surg Oncol Clin N Am 23(3):579–592. https://doi.org/10.1016/j.soc.2014.03.014

25. Allott EH, Shan Y, Chen M et al (2020) Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications. Breast Cancer Res Treat 179(1):185–195. https://doi.org/10.1007/s10549-019-05442-2

26. Sengal AT, Haj Mukhtar NS, Vetter M et al (2018) Comparison of receptor-defined breast cancer subtypes between German and Sudanese women: a facility-based cohort study. J Glob Oncol 4:1–12. https://doi.org/10.1200/JGO.2017.010082

27. Miyagawa Y, Miyake T, Yanai A et al (2015) Association of body mass index with risk of luminal A but not luminal B estrogen receptor-positive and HER2-negative breast cancer for postmenopausal Japanese women. Breast Cancer 22(4):399–405. https://doi.org/10.1007/s12885-013-0493-z

28. Kwan ML, Kroenke CH, Sweeney C et al (2015) Association of high obesity with PAM50 breast cancer intrinsic subtypes and gene expression. BMC Cancer 15:278. https://doi.org/10.1186/s12885-015-1263-4
29. Sørlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874. https://doi.org/10.1073/pnas.191367098

30. Jorns JM (2019) Breast cancer biomarkers: challenges in routine estrogen receptor, progesterone receptor, and HER2/neu evaluation. Arch Pathol Lab Med 143(12):1444–1449. https://doi.org/10.5858/arpa.2019-0205-RA

31. Ziegenhorn H-V, Frie KG, Ekanem I-O et al (2020) Breast cancer pathology services in Sub-Saharan Africa: a survey within population-based cancer registries. BMC Health Serv Res. https://doi.org/10.1186/s12913-020-05752-y

32. Balic M, Thomssen C, Würstlein R et al (2019) St. Gallen/Vienna 2019: a brief summary of the consensus discussion on the optimal primary breast cancer treatment. Breast Care 14(2):103–110. https://doi.org/10.1159/000499931

33. Jensen M-B, Lænkholm A-V, Nielsen TO et al (2018) The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer. Breast Cancer Res. https://doi.org/10.1186/s13058-018-1012-0

34. Chia SK, Bramwell VH, Tu D et al (2012) A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res 18(16):4465–4472. https://doi.org/10.1158/1078-0432.CCR-12-0286

35. Lehmann BD, Bauer JA, Chen X et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig 121(7):2750–2767. https://doi.org/10.1172/JCI45014

36. Hartung C, Porsch M, Stückerth K et al (2021) Identifying high-risk triple-negative breast cancer patients by molecular subtyping. Breast Care 16(6):637–647. https://doi.org/10.1159/000519255

37. Getachew S, Addisie A, Seife E et al (2022) Breast nurse intervention to improve adherence to endocrine therapy among breast cancer patients in South Ethiopia. Oncologist 27(8):e650–e660. https://doi.org/10.1093/oncolo/oyac081

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.